Nascent Biotech (Nascent Biotech) ROCE % : -12,133.33% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Nascent Biotech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nascent Biotech's annualized ROCE % for the quarter that ended in Dec. 2023 was -12,133.33%.

Nascent Biotech ROCE % Historical Data

The historical data trend for Nascent Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nascent Biotech ROCE % Chart

Nascent Biotech Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

Nascent Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-12,133.33

Nascent Biotech ROCE % Calculation

Nascent Biotech's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-1.078	/	( ( (0.105 - 0.777)	+	(0.255 - 1.551) )	/ 2 )
	=	-1.078	/	( (-0.672	+	-1.296)	/ 2 )
	=	-1.078	/	-0.984
	=	109.55 %

Nascent Biotech's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-1.456	/	( ( (1.043 - 1.049)	+	(0.641 - 0.611) )	/ 2 )
	=	-1.456	/	( ( -0.006	+	0.03 )	/ 2 )
	=	-1.456	/	0.012
	=	-12,133.33 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Nascent Biotech (OTCPK:NBIO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nascent Biotech ROCE % Related Terms

Thank you for viewing the detailed overview of Nascent Biotech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nascent Biotech (Nascent Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408

Website

https://www.nascentbiotech.com

Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.

Executives

Lowell Thomas Holden	director, officer: CFO	631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Sean Carrick	director, officer: President	631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Brandon Price	director, officer: Senior VP Business Development	6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121
Douglas John Karas	director	631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Mark Glassy	director, officer: CEO	6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121